首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到20条相似文献,搜索用时 15 毫秒
1.
The interplay in prostate cancer bone metastases between the 'seed' (the prostate cancer cells) and the 'soil' (the bone microenvironment) has been increasingly recognized as integral to the remarkable tropism for bone shown by prostate cancer. Increasing research into this area is elucidating the mechanisms involved in this complex 'cross-talk'. Recent developments, including the use of bisphosphonates in metastatic disease, highlight the important role of bone cells in the development and progression of metastatic prostate cancer. We review the current reports emphasising these possible mechanisms and indicating possible factors for future treatment directions.  相似文献   

2.
3.
4.
5.
Both the definition and therapy of advanced prostate cancer is challenging. The advanced prostate cancer session at "The 8th International Prostate Cancer Update" had discussions which tried to answer the questions of management of these patients who either present with advanced disease or fail any form of therapy for clinically confined prostate cancer. This article provides an overview of therapeutic options: monotherapy and minimal androgen blockade options versus maximal androgen blockade, adjuvant therapy, intermittent therapy and timing of therapy as well as chemotherapy when all these measures fail. The impact of these therapies on progression as well as quality of life is reviewed.  相似文献   

6.
7.
Local-regional prostate cancer   总被引:1,自引:0,他引:1  
Historically, locally advanced prostate cancer was defined clinically with the digital rectal exam (DRE). With the introduction of screening prostate specific antigen (PSA), further pretreatment stratification of locally advanced prostate cancer was possible. Tables and nomograms have been developed to predict pathologic staging prior to therapy. By combining DRE, PSA, Gleason score, and clinical staging, a patient's probability of treatment failure is estimated, thereby stratifying the risk of locally advanced disease. Pretreatment PSA velocity (PSAV) and PSA doubling time (PSADT) will likely continue to play a role in defining locally advanced prostate cancer. Imaging studies, especially high-field strength pelvic MRI, may provide additional information regarding the presence of locally advanced prostate cancer. In the future, molecular or genetic testing may permit further stratification of patients with locally advanced disease, who are at variable risk for recurrence and death after treatment. Future trials will need to assess the utility of multimodality treatments for patients in the diverse classification of locally advanced prostate cancer.  相似文献   

8.
Summary For decades the palliation of prostate cancer has centered around hormonal manipulation using orchiectomy or estrogen administration. Newer modalities, such as LHRH agonists and nonsteroidal antiandrogens, are now available. Patients receiving combination therapy enjoy superior progression-free and median survival rates.  相似文献   

9.
Hormone-refractory prostate cancer   总被引:2,自引:0,他引:2  
Hormone-refractory prostate cancer is an advanced stage of the metastatic disease; it has a poor prognosis and a short median survival, about 9 to 18 months. The current article is based on a literature review regarding the prognostic factors and medical treatments, with a focus on recent advances in chemotherapy. With the use of docetaxel that increases the median survival of this disease and improves the symptoms, new clinical protocols have been developed, with promising results; these protocols propose a combination with calcitriol or antiangiogenic agents. Supportive care is also an important part of the treatment due to the high level of bone involvement and its consequences. Such recent advances constitute a real progress in the management of prostate cancer, namely the pharmacological combinations with a promising efficacy and little toxicity.  相似文献   

10.
Localized prostate cancer   总被引:3,自引:0,他引:3  
  相似文献   

11.
Prostate cancer is the most commonly diagnosed cancer in men. At present, patients are selected for prostate biopsy on the basis of age, serum prostate specific antigen (PSA), and prostatic digital rectal examination (DRE) findings. However, due to limitations in the use of PSA and DRE, many patients undergo unnecessary prostate biopsy. A further problem arises as many patients are diagnosed and treated for indolent disease. This review of the literature highlights the strengths and weaknesses of existing methods of prebiopsy risk stratification and evaluates promising serum, urine, and radiologic prostate cancer biomarkers, which may improve risk stratification for prostate biopsy in the future.  相似文献   

12.
13.
Transrectal ultrasonography has been considered useful for the diagnosis of prostate cancer. There have been few reports on localized cancer in the prostate diagnosed by echogram. In this paper, we discuss echograms of the prostate in cases of localized cancer, advanced cancer and well-controlled cancer. Hypoechoic lesions seem to suggest prostate cancer.  相似文献   

14.
Frimmel H  Egevad L  Bengtsson E  Busch C 《Urology》1999,54(6):1028-1034
Objectives. To use computer-assisted three-dimensional (3D) reconstruction to study cancer distribution in the prostate. The distributions have been determined using data from 81 prostates surgically removed because of cancer.Methods. The pattern of distribution was determined by reshaping (morphing) all prostates in the same size category (small, medium, large) into the same shape and by overlayering the 3D distribution of all cancers into a “unit prostate.” Also, the pattern of 3D distribution was defined for small, medium, and large volume cancers.Results. The study yielded a clear, visual “scatter diagram” representation of the statistics of prostate cancer distribution. It confirmed previous general knowledge: small cancers are mainly found in the lower one third and principally in the dorsolateral part of the gland.Conclusions. This report is part of the investigations preliminary to establishing an optimal protocol for needle biopsy of prostate cancer.  相似文献   

15.

Context

Widespread mass screening of prostate cancer (PCa) is not recommended because the balance between benefits and harms is still not well established. The achieved mortality reduction comes with considerable harm such as unnecessary biopsies, overdiagnoses, and overtreatment. Therefore, patient stratification with regard to PCa risk and aggressiveness is necessary to identify those men who are at risk and may actually benefit from early detection.

Objective

This review critically examines the current evidence regarding risk-based PCa screening.

Evidence acquisition

A search of the literature was performed using the Medline database. Further studies were selected based on manual searches of reference lists and review articles.

Evidence synthesis

Prostate-specific antigen (PSA) has been shown to be the single most significant predictive factor for identifying men at increased risk of developing PCa. Especially in men with no additional risk factors, PSA alone provides an appropriate marker up to 30 yr into the future. After assessment of an early PSA test, the screening frequency may be determined based on individualized risk. A limited list of additional factors such as age, comorbidity, prostate volume, family history, ethnicity, and previous biopsy status have been identified to modify risk and are important for consideration in routine practice. In men with a known PSA, risk calculators may hold the promise of identifying those who are at increased risk of having PCa and are therefore candidates for biopsy.

Conclusions

PSA testing may serve as the foundation for a more risk-based assessment. However, the decision to undergo early PSA testing should be a shared one between the patient and his physician based on information balancing its advantages and disadvantages.  相似文献   

16.
Whereas androgen deprivation and chemotherapy have become the cornerstone of therapy for advanced prostate cancer, novel therapies are being developed that may expand upon currently available treatments. The identification of antigens expressed by prostate tissue and/or prostate cancer that are recognized by T cells or antibodies creates opportunities to develop novel immunotherapeutic approaches including tumor vaccines. Proteins expressed in prostate cancer including prostate-specific antigen, prostatic acid phosphatase, and prostate membrane antigen have been used as immunologic targets for immunotherapy. Moreover, innovations in cancer genomics and proteomics also will aid in the identification of immunologic targets. Emerging trials have demonstrated that immunotherapy may not only generate immune responses in patients, but also clinical responses. Future studies will be directed at capitalizing on these findings.  相似文献   

17.
前列腺癌的放射治疗   总被引:1,自引:0,他引:1  
在前列腺癌的治疗中,放疗具有重要的作用。早期前列腺癌放疗可达到根治目的,疗效与前列腺癌根治术相近。局部晚期前列腺癌的治疗则以放疗为主,已远处转移的前列腺癌放疗也可取得减轻症状,改善生存质量的目的。放疗具有疗效好,适应证广,并发症相对少和治疗后患者生存质量高等优点。放疗的外照射一、常规外照射前列腺的放疗因20世纪50年代引入兆伏射线治疗技术后,已成为前列腺癌治疗的主要方法之一。Kuban等报告652例前列腺癌体外照射的疗效,10年无病生存率T1b66%,T2a57%,T3b、T3c48%,T3-429%;生化无病生存率(biochemical dis-ease-free su…  相似文献   

18.
19.
20.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号